Princess Margaret Cancer Centre, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
Present Address: Centre Hospitalier de Haguenau, Haguenau, France.
BMC Cancer. 2023 Sep 29;23(1):919. doi: 10.1186/s12885-023-11380-6.
This retrospective analysis of data from clinical trials in metastatic urothelial carcinoma (mUC) was conducted to determine baseline patient characteristics associated with long-term survival (LTS) following treatment with immune checkpoint inhibitors.
Data for this analysis were from patients with platinum-refractory mUC who received durvalumab or durvalumab plus tremelimumab in phase 1/2 studies. The primary outcome measure was LTS. Patients were categorised as overall survival (OS) ≥ 2 years (from first dose) or OS < 2 years. A univariable analysis assessed independent associations with LTS and multivariable logistic regression was employed including each variable with P ≤ 0.05 as covariates.
Among 360 patients, 88 (24.4%) had OS ≥ 2 years and 272 (75.6%) had OS < 2 years. In univariable analysis, several baseline characteristics and laboratory measurements were associated with LTS including sex, ECOG PS, PD-L1 expression, prior surgery, time from initial diagnosis, lymph node-only involvement, visceral disease, haemoglobin level, absolute neutrophil count, neutrophil-lymphocyte ratio and lactate dehydrogenase level. In multivariable analysis, LTS was significantly associated with ECOG PS, PD-L1 expression, haemoglobin level and absolute neutrophil count.
Several baseline clinical characteristics and laboratory measurements were associated with LTS for patients with platinum-refractory mUC treated with durvalumab or durvalumab plus tremelimumab.
本回顾性分析对转移性尿路上皮癌（mUC）临床试验数据进行了分析，以确定接受免疫检查点抑制剂治疗后与长期生存（LTS）相关的基线患者特征。
本分析的数据来自接受度伐鲁单抗或度伐鲁单抗联合替西木单抗治疗的铂类难治性 mUC 患者的 1/2 期研究。主要结局指标为 LTS。将患者分为总生存期（OS）≥2 年（从首次剂量开始）或 OS<2 年。单变量分析评估与 LTS 的独立关联，并采用多变量逻辑回归，包括 P≤0.05 的每个变量作为协变量。
在 360 名患者中，88 名（24.4%）OS≥2 年，272 名（75.6%）OS<2 年。单变量分析显示，一些基线特征和实验室测量值与 LTS 相关，包括性别、ECOG PS、PD-L1 表达、既往手术、从初始诊断到治疗的时间、仅淋巴结受累、内脏疾病、血红蛋白水平、绝对中性粒细胞计数、中性粒细胞与淋巴细胞比值和乳酸脱氢酶水平。多变量分析显示，ECOG PS、PD-L1 表达、血红蛋白水平和绝对中性粒细胞计数与 LTS 显著相关。
接受度伐鲁单抗或度伐鲁单抗联合替西木单抗治疗的铂类难治性 mUC 患者的一些基线临床特征和实验室测量值与 LTS 相关。
